Please use this identifier to cite or link to this item: https://doi.org/10.1182/blood-2012-03-415307
Title: Phase 2 study of subcutaneous omacetaxine mepesuccinate after TKI failure in patients with chronic-phase CML with T315I mutation
Authors: Cortes, J.
Lipton, J.H.
Rea, D.
Digumarti, R.
Chuah, C. 
Nanda, N.
Benichou, A.-C.
Craig, A.R.
Michallet, M.
Nicolini, F.E.
Kantarjian, H.
Issue Date: 27-Sep-2012
Citation: Cortes, J., Lipton, J.H., Rea, D., Digumarti, R., Chuah, C., Nanda, N., Benichou, A.-C., Craig, A.R., Michallet, M., Nicolini, F.E., Kantarjian, H. (2012-09-27). Phase 2 study of subcutaneous omacetaxine mepesuccinate after TKI failure in patients with chronic-phase CML with T315I mutation. Blood 120 (13) : 2573-2580. ScholarBank@NUS Repository. https://doi.org/10.1182/blood-2012-03-415307
Abstract: Chronic myeloid leukemia (CML) patients with the BCR-ABL T315I mutation do not benefit from therapy with currently approved tyrosine kinase inhibitors. Omacetaxine mepesuccinate is a protein synthesis inhibitor that has demonstrated activity in cells harboring the T315I mutation. This phase 2 trial assessed the efficacy of omacetaxine in CML patients with T315I and tyrosine kinase inhibitor failure. Patients received subcutaneous omacetaxine 1.25 mg/m2 twice daily, days 1-14, every 28 days until hematologic response or a maximum of 6 cycles, and then days 1-7 every 28 days as maintenance. Results for patients treated in chronic phase are reported here. Patients (n - 62) received a median of 7 (range, 1-41) cycles. Complete hematologic response was achieved in 48 patients (77%; 95% lower confidence limit, 65%); median response duration was 9.1 months. Fourteen patients (23%; 95% lower confidence limit, 13%) achieved major cytogenetic response, including complete cytogenetic response in 10 (16%). Median progression free-survival was 7.7 months. Grade 3/4 hematologic toxicity included thrombocytopenia (76%), neutropenia (44%), and anemia (39%) and was typically manageable by dose reduction. Nonhematologic adverse events were mostly grade 1/2 and included infection (42%), diarrhea (40%), and nausea (34%). Omacetaxine may provide a safe and effective treatment for CML patients with T315I mutation. This study is registered at www.clinicaltrials.gov as NCT00375219. © 2012 by The American Society of Hematology.
Source Title: Blood
URI: http://scholarbank.nus.edu.sg/handle/10635/128647
ISSN: 00064971
DOI: 10.1182/blood-2012-03-415307
Appears in Collections:Staff Publications

Show full item record
Files in This Item:
There are no files associated with this item.

SCOPUSTM   
Citations

110
checked on Oct 23, 2021

WEB OF SCIENCETM
Citations

91
checked on Oct 15, 2021

Page view(s)

58
checked on Oct 14, 2021

Google ScholarTM

Check

Altmetric


Items in DSpace are protected by copyright, with all rights reserved, unless otherwise indicated.